Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a cl ...